# OnCo record paper-libretto-001-selpercatinib-nsclc-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-libretto-001-selpercatinib-nsclc-nejm-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-libretto-001-selpercatinib-nsclc-nejm-2020" ;
  schema:name "LIBRETTO-001: selpercatinib in RET fusion-positive non-small-cell lung cancer"@en ;
  schema:description "The selective RET inhibitor selpercatinib shrank tumours in 64 percent of previously treated and 85 percent of untreated patients with RET fusion-positive lung cancer, including brain metastases, and led to the first approval for this driver."@en ;
  schema:url <https://onco.cc/key-papers/paper-libretto-001-selpercatinib-nsclc-nejm-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2005653>, <https://pubmed.ncbi.nlm.nih.gov/32846060/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2005653> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Drilon A, Oxnard GR, Tan DSW, et al." ;
  onco:cancers <https://onco.cc/cancers/ret-fusion-nsclc/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/> ;
  onco:journals <https://onco.cc/journals/nejm/> .